REG - Immupharma PLC - Publication of Circular

ImmuPharmaAnnouncement

Yesterday 09:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260319:nRSS3073Xa&default-theme=true

RNS Number : 3073X  Immupharma PLC  19 March 2026

19 March 2026

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Publication of Circular

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company announces that further to its 'Fundraising' announcement, published on
17 March 2026 at 7:00 a.m. (the "Fundraising RNS"), a circular convening a
General Meeting has today been sent to shareholders.

 

The General Meeting is scheduled to be held at 11.00 a.m. (GMT) on 7 April
2026, at the offices of Broadfield Law UK LLP, One Bartholomew Close, London
EC1A 7BL.

 

A copy of the Circular will be available shortly, in electronic form, for
download on the Company's website www.immupharma.co.uk.
(http://www.immupharma.co.uk)

 

Terms used but not defined in this announcement have the same meaning as set
out in the Fundraising RNS.

 

For further information, please contact:

 

 ImmuPharma PLC (www.immupharma.co.uk.)      +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations    + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)     +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)    44 (0) 20 3650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                   +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives.

For additional information about ImmuPharma please visit
 www.immupharma.co.uk. (http://www.immupharma.co.uk)

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CIRGZGMFRLZGVZG



            Copyright 2019 Regulatory News Service, all rights reserved